Why ChemoCentryx Shares Are Plunging Today

ChemoCentryx CCXI shares are trading lower following a vote from the FDA panel on whether the efficacy data support approval on its Avacopan in ANCA-Associated vasculitis.

The vote on whether the FDA should approve the drug was preceded by a split vote of 9 to 9 on whether the efficacy data support approval, and 10 to 8 that the safety profile of avacopan is adequate to support approval.

ChemoCentryx is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer.

ChemoCentryx shares were trading 60.7% lower at $10.82 per share on Friday. The company set a new 52-week high of $70.29 and has a 52-week low of $9.55.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Small CapMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!